Literature DB >> 14607797

Striatal neural grafting improves cortical metabolism in Huntington's disease patients.

Véronique Gaura1, Anne-Catherine Bachoud-Lévi, Maria-Joao Ribeiro, Jean-Paul Nguyen, Vincent Frouin, Sophie Baudic, Pierre Brugières, Jean-François Mangin, Marie-Françoise Boissé, Stéphane Palfi, Pierre Cesaro, Yves Samson, Philippe Hantraye, Marc Peschanski, Philippe Remy.   

Abstract

Huntington's disease is a hereditary disease in which degeneration of neurons in the striatum leads to motor and cognitive deficits. Foetal striatal allografts reverse these deficits in phenotypic models of Huntington's disease developed in primates. A recent open-label pilot study has shown some clinical improvement or stabilization in three out of five Huntington's disease patients who received bilateral striatal grafts of foetal neurons. We show here that the clinical changes in these three patients were associated with a reduction of the striatal and cortical hypometabolism, demonstrating that grafts were able to restore the function of striato-cortical loops. Conversely, in the two patients not improved by the grafts, striatal and cortical hypometabolism progressed over the 2-year follow-up. Finally, detailed anatomical-functional analysis of the grafted striata, enabled by the 3D fusion of MRI and metabolic images, revealed considerable heterogeneity in the anatomic and metabolic profiles of grafted tissue, both within and between Huntington's disease patients. Our results demonstrate the usefulness of PET measurements of brain glucose metabolism in understanding the effects of foetal grafts in patients with Huntington's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607797     DOI: 10.1093/brain/awh003

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  32 in total

Review 1.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

Review 2.  Imaging in cell-based therapy for neurodegenerative diseases.

Authors:  Deniz Kirik; Nathalie Breysse; Tomas Björklund; Laurent Besret; Philippe Hantraye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

Review 3.  The design of clinical trials for cell transplantation into the central nervous system.

Authors:  Pierre Cesaro
Journal:  NeuroRx       Date:  2004-10

Review 4.  Cell therapy in Huntington's disease.

Authors:  Stephen B Dunnett; Anne E Rosser
Journal:  NeuroRx       Date:  2004-10

5.  The relationship between excitement symptom severity and extrastriatal dopamine D2/3 receptor availability in patients with schizophrenia: a high-resolution PET study with [18F]fallypride.

Authors:  Yo-Han Joo; Jeong-Hee Kim; Young-Don Son; Hang-Keun Kim; Yeon-Jeong Shin; Sang-Yoon Lee; Jong-Hoon Kim
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-16       Impact factor: 5.270

Review 6.  Mesenchymal stem cells for the treatment of neurodegenerative disease.

Authors:  Nanette Joyce; Geralyn Annett; Louisa Wirthlin; Scott Olson; Gerhard Bauer; Jan A Nolta
Journal:  Regen Med       Date:  2010-11       Impact factor: 3.806

Review 7.  Cellular therapy and induced neuronal replacement for Huntington's disease.

Authors:  Abdellatif Benraiss; Steven A Goldman
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

Review 8.  Functional imaging in Huntington's disease.

Authors:  Jane S Paulsen
Journal:  Exp Neurol       Date:  2009-01-03       Impact factor: 5.330

9.  Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats.

Authors:  Laetitia Aubry; Aurore Bugi; Nathalie Lefort; France Rousseau; Marc Peschanski; Anselme L Perrier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-15       Impact factor: 11.205

10.  Association Between Motor Symptoms and Brain Metabolism in Early Huntington Disease.

Authors:  Véronique Gaura; Sonia Lavisse; Pierre Payoux; Serge Goldman; Christophe Verny; Pierre Krystkowiak; Philippe Damier; Frédéric Supiot; Anne-Catherine Bachoud-Levi; Philippe Remy
Journal:  JAMA Neurol       Date:  2017-09-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.